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UV Fingerprints Predominate in the PTCH Mutation
Spectra of Basal Cell Carcinomas Independent of
Clinical Phenotype
Ellen Heitzer1, Anita Lassacher1, Franz Quehenberger2, Helmut Kerl3 and Peter Wolf1,3
Basal cell carcinoma (BCC) shows a wide interpatient variation in lesion accrual. To determine whether certain
tumorigenic fingerprints and potentially predisposing patched (PTCH) tumor suppressor single-nucleotide
polymorphisms (SNPs) are distributed differently among sporadic BCC patients, we compared the PTCH
mutation spectra in early-onset BCC (first lesion at ageo35 years), regular BCC (first lesion at ageX35 years and
o10 lesions), and multiple BCC (X10 lesions). The PTCH gene was mutated in 29 of 60 cases (48%). Most of the
PTCH mutations bore the UV fingerprint (i.e., C-T or tandem CC-TT transitions at dipyrimidine sites).
However, neither the proportion nor the spectra of exonic PTCH mutations differed significantly among the
three groups. A large number of SNPs (IVS10þ 99C/T, IVS11-51G/C, 1665T/C, 1686C/T, IVS15þ 9G/C, IVS16-80G/C,
IVS17þ 21G/A, and 3944C/T or its combinations) were also detected, but again their incidence did not differ
significantly among the groups. Interestingly, expression of the IVS16-80G/C and the IVS17þ 21G/A genotype
did not achieve the Hardy–Weinberg equilibrium in patients with regular and/or early-onset BCC. These data
suggest that a (UV-) mutated PTCH gene is important for sporadic BCC formation independent of clinical
phenotype and that the IVS16-80G/C and/or IVS17þ 21G/A SNP site might be important for tumorigenesis in
certain BCC patients.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common cancer
in humans. The American Cancer Society estimates that,
in the United States alone, more than 800,000 new cases
are diagnosed each year (http://www.skincancer.org/).
The pathogenic role of UV radiation in BCC tumori-
genesis is clear. Most BCCs occur on sun-exposed body
sites, and BCC incidence correlates unambiguously with sun
exposure (Scotto et al., 1996; Gailani et al., 1996a; Kerb
et al., 1997, and citations therein). Xeroderma pigmentosum
(XP), a hereditary disease involving defective DNA repair and
the generation of UV-induced DNA photoproducts, is
associated with an increased incidence of skin cancers
including BCC. Non-melanoma skin cancers including
BCC characteristically exhibit UV fingerprint mutations
(i.e., C-T or tandem CC-TT transitions at dipyrimidine
sites) in tumor suppressor genes such as p53, patched (PTCH),
and INK-4-ARF and in proto-oncogenes such as Ras (Seidl
et al., 2001; Kreimer-Erlacher et al., 2001, 2003; Wolf et al.,
2004). Moreover, according to evidence from transgenic
animal studies with PTCHþ / mice, UV exposure leads to
the formation of BCC-like lesions (Aszterbaum et al., 1999).
However, even though UV exposure is considered
the major risk factor for BCC, recent research suggests that
some individuals may also be genetically predisposed to
the disease (Heagerty et al., 1994; Hoban et al., 2002;
Strange et al., 2002). Indeed, a striking characteristic of BCC
is the extent to which tumor accrual varies among patients
(Ramachandran et al., 2000). In the case of sporadic
BCC, some patients may have only a solitary lesion at
presentation and during follow-up, whereas others may
exhibit multiple lesions at presentation and clustering of
lesions during follow-up (Ramachandran et al., 1999; and
references cited therein). At our institution, we have
identified over the last decade more than 16,000 patients
with more than 32,000 BCC lesions (Ferra, 2002; P Wolf
et al., unpublished data). Of interest is that more than
200 patients in this patient population had early-onset BCC
(i.e., their first BCC lesion was diagnosed before the age of 35
years), whereas another 245 patients had multiple BCCs
(i.e., X10 lesions). As others have previously suggested
(Ramachandran et al., 1999), it seems unlikely that diffe-
rences in UV exposure alone would account for these
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different BCC phenotypes. Indeed, a multivariate statistical
analysis of phenotype, genotype, and environmental factors
in our patient population revealed that the most significant
independent risk factor in having single versus multiple BCC
lesions, besides a history of painful or blistering sunburns
(odds ratio of 2.4), was a family history of skin cancer (odds
ratio of 6.0) (P Wolf et al., unpublished data).
The most important recent advance in understanding the
molecular biology of BCC has been the discovery that
germline mutations in the human homologue of the
Drosophila PTCH gene cause nevoid basal cell carcinoma
syndrome (NBCCS) (Hahn et al., 1996a; Johnson et al., 1996).
This rare autosomal-dominant disorder, which is also known
as Gorlin syndrome (Gorlin, 1987), is characterized by
frequent BCC lesions and is associated with an increased
risk of developing other tumors (e.g., medulloblastomas,
ovarian fibromas, meningiomas, fibrosarcomas, rhabdomyo-
sarcomas, and cardiac fibromas). Phenotypically, patients
with NBCCS exhibit odontogenic jaw cysts, palmar and
plantar pits, and developmental abnormalities such as rib and
craniofacial skeletal alterations. These patients inherit in all of
their normal cells a mutation on one allele of the PTCH gene;
moreover, BCCs and other tumors in these patients exhibit a
second somatic mutation and/or loss of heterozygosity (LOH),
thereby fulfilling the criteria of the two-hit model of
molecular carcinogenesis and identifying PTCH as a tumor
suppressor gene (Hahn et al., 1996b; Unden et al., 1996).
Shortly after this identification of PTCH as a tumor
suppressor gene, Hahn et al. (1996a) isolated the complete
human PTCH cDNA and mapped the gene to chromosome
9q22.3. Others subsequently determined that the PTCH gene
encodes a transmembrane protein that functions as a receptor
for the hedgehog family of proteins (Stone et al., 1996).
Binding of hedgehog to PTCH induces the release and
activation of another cellular-membrane protein called
smoothened. Release of the smoothened protein activates the
downstream signalling pathway, which leads to the induction
of a number of proteins via the Gli1 transcription factor,
including transforming growth factor-b (Heberlein et al.,
1993), platelet-derived growth factor receptor-a (Xie et al.,
2001), Gli (Dahmane et al., 1997), and even PTCH itself
(Unden et al., 1997). From studies in Drosophila, it is known
that in the absence of hedgehog, PTCH and smoothened form
a complex that keeps smoothened in an inactive state (Bale
and Yu, 2001). A recent report by Bijlsma et al. (2006) showed
that smoothened can be repressed by PTCH-dependent
(pro-)vitamin D3 secretion. In skin, hedgehog signalling has
been implicated in hair follicle growth and morphogenesis;
mutational loss of normal PTCH function generates a
constitutive hedgehog signal that promotes proliferation rather
than differentiation. Although these data provide indirect
support for the role of PTCH in BCC tumorigenesis, the exact
mechanisms by which dysregulated hedgehog signalling leads
to BCC tumorigenesis remain to be determined.
In any case, PTCH mutations occur frequently in sporadic
BCC (Gailani et al., 1996b; Hahn et al., 1996b; Unden et al.,
1996) and XP-associated BCC (Bodak et al., 1999; D’Errico et al.,
2000). They are also just as likely to occur in minute BCC lesions
as in larger ones; and all histological subtypes of BCC, whether
primary or recurrent, frequently exhibit LOH or PTCH mutation
(Gailani et al., 1996b; Unden et al., 1996; Bodak et al., 1999;
D’Errico et al., 2000). In this study, we analyzed the PTCH gene
sequences in tumor specimens from three phenotypically distinct
groups of patients in order to identify potential differences in
their PTCH mutation spectra and potential tumor-causing agents,
risk factors, and tumor-predisposing PTCH variants.
RESULTS
Patient demographics and clinical characteristics
Selected demographic and clinical characteristics of the
patients whose archived tumors were analyzed in this study
are summarized in Materials and Methods.
High overall frequency of exonic UV fingerprints on the PTCH
gene in BCC
As shown by PCR and subsequent direct automated sequen-
cing of the PTCH gene (exons 2–23), exonic missense/stop
base and/or intronic splice site PTCH mutations were found
in 29 of 60 BCC (48%). Exonic PTCH mutations (n¼28)
occurred frequently in all three patient groups. These
mutations originated most frequently from group A (43%
(12/28)) and group C (39% (11/28)) and less from group B
(18% (5/28)) (Table 1 and Figure 1). Of note, one tumor from
group A (A14) and two tumors from group C (C2 and C4)
carried two PTCH mutations. Statistical analysis revealed no
significant differences in the number and type of exonic
mutations among the different groups. Most of the exonic
mutations (68% (19/28)) bore the UV fingerprint of C-T
transition (63% (12/19)) or tandem CC-TT transitions (37%
(7/19)) at dipyrimidine sites. The remaining mutations were
classified as being of either the reactive oxygen species (ROS)
fingerprint (i.e., G:C-T:A transversion) (11% (3/28)) or other
type (21% (6/28)). Only two tumors (A12 and C4) had the
same mutation (i.e., a C-T transition at codon 1051).
Interestingly, most of the exonic mutations that were detected
(54% (15/28)) were nonsense mutations, whose predicted
amino-acid sequence encoded a stop signal (Table 2).
Mutations in the PTCH protein occurred predominantly in
the extracellular loop (ECL) (54% (15/28)) and the transmem-
brane domain (TMD) (25% (7/28)). The remainder occurred
in the cytoplasmic loop (11% (3/11)), N-terminus (7% (2/28)),
and C-terminus (4% (1/28)). The ECL mutations were further
distributed among the ECL1 (8 (29%)), ECL3 (1 (4%)]), and
ECL4 (6 (21%)). Those in the TMD were further distributed
among the TMD1 (1 (4%)), TMD2 (1 (4%)), TMD3 (1 (4%)),
TMD4 (1 (4%)), TMD5 (2 (7%)), and TMD12 (1 (4%)). Those
in the cytoplasmic loop were further distributed among the
cytoplasmic loop 2 (1 (4%)) and cytoplasmic loop 4 (2 (7%)).
However, when analyzed for homogeneity of mutation
distribution with regard to the size of the different domains,
the predominance of mutations at the ECL1, ECL4, and TMD
sites did not reach statistical significance, as the observed
mutation frequencies in those regions were close to the
expected mutation frequencies and fell within the 95%
confidence intervals (data not shown). In addition, eight silent
mutations were detected in group A and four in group B.
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Table 1. PTCH mutations in BCCs from different patient groups
Group1 Tumor
Exon/intronic
position Codon
Codon
surrounding
sequence2
Base
change Strand3
Amino-acid
change
Location in
protein4
Type of
mutation5
A A2 12 568 tCCCg CC-TT T Pro-Leu TMD 5 UV
A4 12 539 gGAGt G-T T Glu-Stop CPL 2 ROS
A7 12 563 cGCGt C-T T Ala-Val TMD 5 Other
A9 6 278 cCCAg C-T NT Trp-Stop ECL 1 UV
A12 18 1051 tCCAg C-T NT Trp-Stop CPL 4 UV
A13 5 237 cTTCc C-T NT Glu-Lys ECL 1 UV
A14 11 504 aTGGc G-T NT Pro-Gln TMD 4 ROS
22 1237 gCTCc CC-TT NT Glu-Lys N-term UV
A15 9 417 tCAAa C-T T Gln-Stop ECL 1 UV
A18 23 1396 gTCCc C-T NT Gly-Arg N-term UV
A19 17 926 cCCAa CC-TT NT Trp-Stop ECL 4 UV
A20 3 184 cCAGg CC-TT T Gln-Stop ECL 1 UV
B B1 15 816 cCAGc C-T T Gln-Stop ECL 4 UV
B2 10 494 tTCCt C-T T Ser-Phe TMD 2 UV
IVS10-19 — ccccc C-T T — — UV
IVS10+68 — gccag C-T T — — UV
B5 IVS19+16 — ttcaa C-T NT — — UV
B6 3 159 gATAc A-T T Ile-Leu ECL 1 Other
B7 2 115 aTCCc CC-TT NT Gly-Lys TMD 1 UV
B9 IVS13+34 — accca C-T NT — — UV
B12 IVS20+1 — tacCT C-T NT — — UV; splice
B14 IVS13-1 — GCctg C-T NT — — UV; splice
B18 IVS9-6 — gacca C-T T — — UV
B20 12 576 cCAGg C-T T Gln-Stop ECL 3 UV
C C2 3 149 gaGAAga G-T T Glu-Stop ECL 1 ROS
18 1016 tcCTCtt C-T T Leu-Phe ECL 4 UV
C3 10 480 tgTCAgt C-G T Ser-Stop TMD 3 Other
IVS13+3 — gtaca A-T T — — Other splice
C4 2 96 aaAAAaa A-T T Lys-Stop C-term Other
18 1051 gtCCAgg C-T NT Trp-Stop CPL 4 UV
C5 8 390 agGACaa GG-AT T Asp-Tyr ECL 1 Other
C6 5 236 tcCCAga CC-TT NT Trp-Stop ECL 1 UV
C8 18 1018 tcCCAga CC-TT NT Trp-Stop ECL 4 UV
IVS19+34 — gaaaa A-C T — — ROS
C9 15 791 ttATTgc T-C T Ile-Thr ECL 4 Other
C14 21 1167 agCCCat C-T NT Gly-Arg TMD 12 UV
C18 IVS+5 — tactg C-T NT — — UV; splice
C19 15 816 cCAGc C-T T Gln-Stop ECL 4 UV
C20 IVS19+1 — tacCA C-T NT — — UV; splice
BCC, basal cell carcinoma; PTCH, patched gene.
1Groups are defined in Materials and Methods: group A, early-onset BCC; group B, multiple BCC; group C, regular BCC.
2The sequence for the strand (transcribed or non-transcribed) containing a pyrimidine at the mutation site is shown in the 50-30 direction. Nucleotides of the
affected codon are written in capital letters. Mutated bases are shown in bold letters.
3Strand with affected pyrimidine: T, transcribed strand; NT, non-transcribed strand.
4Location in the PTCH protein: TMD, transmembrane domain; ECL, extracellular loop; CPL, cytoplasmatic loop; C-term, carboxyl-terminus; N-Term,
amine-terminus.
5Types of mutation are defined in Materials and Methods. UV, UV fingerprint; ROS, reactive oxygen species fingerprint. Splice, mutation that alters the
splice-site consensus sequence.
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Similar to exonic mutations most of these silent mutations
(75% (9/12)) had the UV fingerprint. Subsequent comparison
of DNA from tumor and adjacent normal tissue samples
revealed that every specific mutation, whether silent or not,
occurred only in tumor tissue, thus indicating that each
mutation was somatic.
Presence of intronic PTCH mutations in BCC
In addition to mutations in the coding region of the PTCH
gene, a total of seven intronic mutations were detected in 30%
(6/20) of group B lesions and a total of four intronic mutations
in 20% (4/20) of group C lesions; none were detected in group
A lesions (Table 1). The difference between the number of
intronic mutations in groups B and C versus group A was also
significant (P¼ 0.02). As in the case of the exonic mutations,
most of the observed intronic mutations (82% (9/11)) bore the
UV fingerprint; the remainder were classified as being of either
the ROS fingerprint (9% (1/11)) or other type (9% (1/11)). On
the basis of predicted amino-acid sequences, most of the
intronic mutations (55% (6/11)) would have had no affect on
the splice site of the PTCH gene; approximately one-third
(36% (4/11)) would have affected the 50 splice site, and only
one would have affected the 30 splice site. Interestingly, one
tumor (B2) bore two intronic C-T mutations as well as an
exonic C-T mutation at codon 10 (Table 1). In addition, two
other tumors (C3 and C8) each carried one intronic and one
exonic mutation. Important to note is that intronic mutations in
tumors B12, B14, C3, C18, and C20 apparently led to aberrant
or less efficient splicing. This was indicated by the lowering of
the consensus splice site score in those tumors (Shapiro and
Senapathy, 1987; www.genet.sickkids.on.ca/~ali/splicesite-
score.html) (data not shown).
Comparison of PTCH mutation spectra of BCC in this study
versus in the literature
In our study population, mutation of the PTCH gene, whether
by exonic (missense/stop base) mutation or intronic (splice
site) mutation, was observed in 11 (55%), 7 (35%), and 11
(55%) of BCC in groups A, B, and C, respectively (Table 1 and
Figure 1). The mutation spectra in these three different groups
were compared with mutation spectra for NBCCS-associated
BCC and sporadic BCC recently reported by Lindstro¨m et al.,
(2006). Lindstro¨m et al. (2006) derived their mutation spectra
by pooling data from previous sequencing studies of the
PTCH locus in sporadic, NBCCS-associated, and XP-asso-
ciated BCC. Comparison of our mutation spectra against
those reported by Lindstro¨m et al. (2006) of 249 mutations
that had been included in the PTCH mutation database
(http://www.cybergene.se/cgi-bin/w3-msql/ptchbase/index.
html) as of 30 June 2005 (Figure 1) revealed statistically
significant differences between our overall mutation spectra
and those for NBCCS-associated BCC (Po0,001; w2-test) and
sporadic BCC (P¼0.04). These significant differences were
mainly due to the predominance of deletion/insertion
mutations in the mutation spectra of NBCCS-associated
BCC lesions (66% (87/132)) and the relatively frequent
occurrence of these mutations in sporadic BCC lesions
(30% (26/86)), as reported by Lindstro¨m et al. (2006). In
contrast, we were unable to detect any deletion or insertion
mutations in the BCC lesions obtained from our archives.
Instead, except for seven tandem CC-TT transitions and one
two-nucleotide (GG-AT) substitution in tumor C5, most of
the mutations we detected were single-nucleotide substitu-
tions (Table 1). There was no statistically significant
difference between our mutation spectra data and those of
XP-associated BCC (Lindstro¨m et al., 2006).
Differences in frequency of PTCH single-nucleotide
polymorphism variants and LOH in BCC among patient groups
Eight previously described single-nucleotide polymorphism
(SNP) variants (IVS10þ 99C/T, IVS11–51G/C, 1665T/C,
1686C/T, IVS15þ9G/C, IVS16-80G/C, IVS17þ 21G/A, and
3944C/T) were detected in a large number of BCC in our
study population, and their genotype frequencies for the SNPs
and ancestral alleles are presented in Table 2. Statistical
analysis using a global test (Goeman et al., 2004) revealed a
significant difference in SNP genotype distribution among the
different groups (P¼0.033). Statistical analysis after Bonfer-
roni correction revealed no significant difference in the
frequencies of SNPs among the different BCC groups.
Moreover, with two exceptions, all PTCH SNPs achieved
the Hardy–Weinberg equilibrium in all three BCC groups
(Table 2). The exceptions were the IVS16-80G/C and the
IVS17þ 21G/A locus. Indeed, samples heterozygous for
IVS16-80G/C were significantly less frequent than expected
from the allele frequencies generated for groups A
(P¼0.0232) and C (P¼0.0004) individually and for all three
groups as a whole (P¼ 0.0003). Those samples heterozygous
for IVS17þ21G/A were significantly more frequent than
expected from the allele frequencies generated for group C
(P¼0.0198). Importantly, similar results were obtained for
the SNP analysis when data were subjected to statistical
analysis separately for tumor tissue samples with mutations or
normal tissue samples of tumor adjacent skin of tumors with
mutations or a combination of both (data not shown).
Moreover, when the SNP sequences of interest were
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Figure 1. PTCH mutation spectra of BCC lesions in this study and in the
literature. Tumor samples from three groups of patients seen at our institution
were analyzed for PTCH mutation spectra (n¼20 patients, each group):
group A, early-onset BCC; group B, multiple BCC; group C, regular BCC.
*Percentages for groups A–C are based on the numbers of patients in our study
population (n¼60); percentages for NBCCS-associated BCC, XP-associated
BCC, and sporadic BCC are based on the numbers of patients in the studies
reported in the literature (NBCCS, n¼ 132; XP, n¼ 31; sporadic BCC, n¼ 86)
(Lindstr +om et al., 2006). Tumor samples were analyzed for the presence of UV
fingerprint (UV), deletion/insertion (DEL/INS), ROS fingerprint, and other
mutations. Overall, the mutation spectra in our study population differed
significantly from those reported for NBCCS-associated BCC (Po0.001;
w2-test) and sporadic BCC (P¼0.04) in the literature.
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Table 2. Genotype and allelic frequencies of PTCH variants in BCCs from different patient groups
SNP Group1 p112 p123 p224 p gt5 p16 p27 p allele8 D-HWE9 P HWE10
IVS10+99C/T A 0.85 0.1500 — 0.93 0.07 0.011
B 1.00 — — 1.00 0.00 NA
C 0.80 0.20 — 0.90 0.10 0.020
All 0.88 0.12 — NS 0.94 0.06 NS 0.007 NS
IVS11-51 C/T A 0.55 0.35 0.10 0.73 0.27 0.049
B 0.65 0.20 0.15 0.75 0.25 0.175
C 0.50 0.25 0.25 0.63 0.37 0.219
All 0.57 0.26 0.17 NS 0.70 0.30 NS 0.153 NS
1665 T/C A 0.80 0.10 0.10 0.85 0.15 0.155
B 0.90 0.10 — 0.95 0.05 0.005
C 0.60 0.35 0.05 0.78 0.22 0.001
All 0.77 0.18 0.05 NS 0.86 0.14 NS 0.060 NS
1686 C/T A 0.75 0.25 — 0.88 0.12 0.031 .
B 0.80 0.20 — 0.90 0.10 0.020
C 0.90 0.10 — 0.95 0.05 0.005 .
All 0.82 0.18 — NS 0.91 0.09 NS 0.017 NS
IVS15+9G/C A 0.30 0.40 0.30 0.50 0.50 0.100
B 0.40 0.40 0.20 0.60 0.40 0.080
C 0.25 0.50 0.25 0.50 0.50 0.000
All 0.32 0.43 0.25 NS 0.53 0.47 NS 0.064 NS
IVS16-80 G/C A 0.70 0.15 0.15 0.78 0.22 0.199 0.0232
B 0.25 0.40 0.35 0.45 0.55 0.095 NS
C 0.55 0.10 0.35 0.60 0.40 0.380 0.0004
All 0.50 0.22 0.28 0.0278 0.61 0.39 0.0121 0.260 0.0003
IVS17+21 G/A A 0.20 0.60 0.20 0.50 0.50 0.100
B 0.10 0.45 0.45 0.32 0.68 0.011
C 0.15 0.80 0.05 0.55 0.45 0.305 0.0198
All 0.15 0.62 0.23 0.0460 0.46 0.54 NS 0.120 NS
3944 C/T A 0.35 0.55 0.10 0.63 0.37 0.081
B 0.15 0.50 0.35 0.40 0.60 0.020
C 0.30 0.60 0.10 0.60 0.40 0.120
All 0.27 0.55 0.18 NS 0.54 0.46 NS 0.053 NS
BCC, basal cell carcinoma; NA, not applicable; NS, not significant; PTCH, patched gene; SNP, single-nucleotide polymorphism.
1Groups are defined in Materials and Methods: group A, early-onset BCC; group B, multiple BCC; group C, regular BCC,
2Genotype frequency for homozygous ancestral allele.
3Genotype frequency heterozygous ancestral allele.
4Genotype frequency for homozygous SNP.
5w2 test comparing genotype frequencies among the groups. The global test over all SNPs was significant (P=0.033).
6Allelic frequency for ancestral allele.
7Allelic frequency for SNP.
8w2 test comparing allelic frequencies among groups. The global test over all SNPs was not significant (P=0.054).
9D-HWE (difference from Hardy–Weinberg equilibrium) defined as p12/2 – p1* p2. Negative values indicate less heterozygocity than expected.
10w2 test for Hardy–Weinberg equilibrium (HWE) within each group and for the pooled data. The HWE within groups was only tested when the overall test
revealed a significant difference.
Significant P-values after Bonferroni correction are shown in boldface type.
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compared in PTCH-mutated tumor tissue and adjacent
normal tissue, a change from heterozygosity to homozygosity
suggestive of LOH was noted in many cases (i.e., 5 (45%) in
group A, 3 (60%) in group B, and 5 (55%) in group C)
(Table 3).
DISCUSSION
In one of the largest studies (if not the largest study) of PTCH
gene mutation spectra in sporadic BCC, we have found that
almost half of the tumors we examined bore PTCH gene
mutations (48% (29/60)). Our data, which we obtained by
analyzing archived tumors from three phenotypically distinct
patient groups (i.e., early-onset, multiple, and regular BCC),
also indicate that most of these mutations occurred as exonic
missense/stop base mutations or intronic changes. Moreover,
most of these exonic and intronic mutations (68 and 82%,
respectively) bore the UV fingerprint (i.e., C-T or tandem
CC-TT transitions at dipyrimidine sites), whereas the
remainder bore ROS fingerprint (Ruggeri et al., 1993) or
other types of mutations.
That the percentage and type of exonic PTCH mutations
did not differ significantly among our three patient groups
indicates that a (UV-) mutated PTCH gene is important for
sporadic BCC formation independent of clinical phenotype
(i.e., regular, multiple, or early-onset BCC). It could be
argued that the high overall proportion of UV fingerprint
mutations observed in our study might be due to the overall
predominance of UV fingerprint-bearing lesions originating
in the head and neck region (59% (34/58)). It is presumed that
the head and neck receive cumulatively more sunlight than
do other body sites. Surprisingly, however, taking together
exonic and intronic mutations the proportion of UV
fingerprint-bearing BCC lesions originating on the trunk and
extremities was even greater than the proportion of those
originating in the head and neck region (93% (13/14) vs 58%
(14/24)) (data not shown).
Some investigators have proposed cigarette smoking as a
potential factor or cofactor in BCC formation (Cohen and
Rogers, 1995; Strange et al., 2002), and this hypothesis
certainly has merit. Indeed, one specific mutation identified
in our analyses (i.e., G:C-T:A transversion) has been
attributed to oxidative damage of the kind inflicted by the
polycyclic aromatic hydrocarbon, benzo[a]pyrene, found in
cigarette smoke and crude coal tar products. However, the
relative scarcity of such mutations in our study population
argues against a causative role for this mutation. Only three
such mutations were found in our study population: two in
group A and one in group C. Moreover, it must be
remembered that G:C-T:A transversions may also arise
from oxidative UV(A) damage inflicted via singlet oxygen-
induced production of 8-hydroxyguanosine (Ichihashi et al.,
2003 and references cited therein; Agar et al., 2004).
The overall percentage of PTCH-mutated sporadic BCC
in our study population (48% (29/60)) is consistent with
the percentages (i.e., 40–50%) reported in the literature
(Chidambaram et al., 1996; Gailani et al., 1996b; Hahn et al.,
1996b; Unden et al., 1996; Wolter et al., 1997; Aszterbaum
et al., 1998). However, the main difference between the
mutation spectra of sporadic BCC reported here and in the
literature is the lack of deletions and insertions (Figure 1).
Consequently, the proportion of UV fingerprint mutations in
our study is relatively higher. Indeed, the frequency of C-T
and tandem CC-TT transitions in our population of patients
with sporadic BCC is similar to that reported for a population
of patients with XP-associated BCC (Figure 1). Although we
can offer no definite explanation for this difference, one
possibility is that the PTCH mutation data used in the
previously published studies came from a ‘‘contaminated’’
open data bank. For example, mutations in sporadic BCC that
have been recorded in the PTCH data bank (http://www.
cybergene.se/cgi-bin/w3-msql/ptchbase/index.html) might have
been contaminated by the entry of data obtained from PTCH-
mutated non-sporadic BCC lesions associated with NBCCS or
other syndromes. Such contamination can be ruled out in this
study, however, as all of the BCC specimens that we analyzed
came from a very well-defined and thoroughly screened
population of patients seen at our institution (Ferra, 2002).
A substantial proportion of exonic mutations (36% (10/28))
in our study population occurred at PTCH mutation sites
already entered in the PTCH data bank. Indeed, five tumors
(i.e., A13, A15, A20, B20, and C14) exhibited base changes
identical to those previously entered for the applicable
mutation sites. Conversely, another five tumors (i.e., A4,
A14 (codon 22 mutation), A19, B1, and C8) exhibited base
changes different from those previously entered for the
applicable mutation sites. Consistent with previous work
regarding sporadic BCC (Lindstro¨m et al., 2006), most of the
exonic PTCH mutations in our study population were
clustered in the ECL (54% (15/28)), particularly ECL1 (29%
(8/28)) and ECL4 (21% (6/28)), a region shown to be
functionally important in several studies (Marigo et al.,
1996; Johnson et al., 2000; references cited in Lindstro¨m
et al., 2006). It has been suggested that hedgehog binding
occurs at ECL1 and ECL4 (Marigo et al., 1996) and that
smoothened is inhibited at the large intracellular loop and the
N-terminus (Ming et al., 2002). In our study, a quarter of the
exonic PTCH mutations (25% (7/28)) were located in
different parts of the TMD, including TMD2 through TMD6,
a region that is associated with the sterol-sensing domain.
Some investigators have suggested that the sterol-sensing
domain is an important region in the PTCH protein, as its
proper function is thought to be required for the lipid binding
of Niemann-Pick type C protein, a peptide that is closely
related to PTCH and involved in lipid trafficking (Ohgami
et al., 2004). In addition to the exonic mutations, a substantial
proportion of intronic mutations were detected in patients
with the multiple BCC and regular BCC phenotypes.
Importantly, almost half of the intronic mutations (45%
(5/11)) affected splice sites, which in turn lowered the splice
site consensus scores of the affected lesions considerably
(Shapiro and Senapathy, 1987; www.genet.sickkids.on.ca/
~ali/splicesitescore.html) and apparently led to aberrant or
less efficient splicing.
LOH at chromosome 9q22 has been observed in 60–70% of
BCC tumors, although such estimates of the extent of loss
remain imprecise (Danaee et al., 2006). Previous investigators
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have inferred the loss of PTCH alleles from the loss of
microsatellite markers adjacent to the PTCH gene (Hahn
et al., 1996b; Holmberg et al., 1996; Johnson et al., 1996;
Shen et al., 1999; Ling et al., 2001; Kim et al., 2002; Asplund
et al., 2005; Reifenberger et al., 2005). We did look for
LOH by taking advantage of the presence of a large number
Table 3. Differences in SNP variant sequences in PTCH-mutated tumors and adjacent normal tissue
SNP2
Sample
Sequence
difference1 Tissue IVS10+99C/T IVS11 51C/G 1665 T/C 1686 C/T IVS15 +9G/C IVS16-80G/C IVS17+21G/A 3944 C/T
A2 No
A4 Yes N C3 G/C T C G/C G/C G/A C
T C G/C T C G* G* G/A C
A7 Yes N C/T C T/C C G/C G/C G/A C
T C/T C C* C C* C* G/A C
A9 No
A12 No
A13 Yes N C/T G/C T C/T G/C G G/A C/T
T C/T G/C T C* G/C G G/A C/T
A14 Yes N C G/C T/C C G/C G/C G/A C/T
T C C* T* C G* G* A* C/T
A15 No
A18 Yes N C C T C/T G/C G/C G/A C/T
T C C T C* C* G* G* C/T
A19 No
A20 No
B1 Yes N C G T/C C G/C G/C G/A C/T
T C G T* C G/C G/C G/A C/T
B2 No
B6 Yes N C C T C G G/C G/A C/T
T C C T C G C* A* T*
B7 No
B20 Yes N C G T/C C/T G/C G/C G/A C/T
T C G T* C* G* G* A* C/T
C2 Yes N C G T C C G G/A C
T C G T C C G G* C
C3 No
C4 Yes N C C T/C C/T G/C G/C G/A C/T
T C C T/C C/T C* C* G* C/T
C5 Yes N C C T/C C/T G/C G G/A C/T
T C C T* C* C* G A* C/T
C6 Yes N C G/C T/C C G G G/A C/T
T C G/C T* C G G G/A C/T
C8 Yes N C C T/C C G/C G G/A C/T
T C C T* C G/C G G/A C/T
C9 No
C14 No
C19 No
N, normal tissue; PTCH, patched gene; SNP, single-nucleotide polymorphism; T, tumor tissue.
1Sequence difference at any SNP site.
2Database of single-nucleotide polymorphisms (dbSNP), National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD,
(dbSNP accession). Build ID: rs574688 IVS11-51C/G, rs1805155 1665T/C, rs2066836 1686C/T, rs2066829 IVS15+9G/C, rs2274692 IVS16-8G/C0,
rs2236406 IVS17+21G/A, rs357564 3944C/T. Available at: http://www.ncbi.nlm.nih.gov/SNP/.
3Single letter indicates homozygosity for that base at a specific SNP locus.
*In 13 of 25 samples with PTCH mutations (52%), comparison of normal (heterozygous) and tumor tissue (homozygous) revealed a sequence difference
indicating loss of heterozygosity (LOH).
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of previously described SNPs (i.e., IVS10þ99C/T, IVS11–
51G/C, 1665T/C, 1686C/T, IVS15þ 9G/C, IVS16–80G/C,
IVS17þ 21G/A, and 3944C/T or its combinations). In brief,
we analyzed the sequences of various SNP-containing PTCH
exons in PTCH-mutated tumor tissue and corresponding
adjacent normal tissue. By our estimate, over half of the tissue
pairs we examined (52% (13/25) showed LOH, as manifested
by SNP homozygosity in the tumor specimen but hetero-
zygosity in the normal tissue specimen (Table 3). However,
despite this apparent prevalence of LOH in tumors-bearing
PTCH mutations, it was notable that the tumors did not
always lose the entire PTCH allele. Indeed, some of these
tumors became homozygous for one or more SNPs but
remained heterozygous for others. This is consistent with a
recent report by Soufir et al. (2006), in which microsatellite
analysis showed LOH for large parts (exons 4–23) but not the
entire PTCH gene in a NBCCS case. Large deletions (Soufir
et al., 2006) or, in the case of PTCH-mutated tumors, other
mechanisms, such as nondisjunction and duplication, mitotic
recombination, or gene conversion (Alberts et al., 2002), may
have been responsible for LOH observed in our study.
Although exposure to UV radiation is thought to be the
main risk factor for BCC development, recent studies suggest
that susceptibility to BCC may also be enhanced by allelic
SNP variations in the PTCH gene (Strange et al., 2004a, b;
Asplund et al., 2005; Liboutet et al., 2006). For instance,
Liboutet et al. (2006) reported that the 3944C/C polymorph-
ism (as opposed to the 3944C/T polymorphism) is signifi-
cantly overrepresented in patients with multiple BCC. Strange
et al. (2004a, b) have suggested that PTCH haplotypes
including the 3944C/T polymorphism in combination with
IVS15þ 9G/C or 1686C/T have tumorigenic potential. Thus,
we looked for an association between SNP distribution and
the risk of early-onset and multiple BCC; we found none.
However, we did identify an apparent, although not
significant difference in IVS16-80G/C and IVS17þ 21G/A
genotype frequency among groups (Table 2). We also noted
that the IVS16-80G/C and IVS17þ 21G/A genotype fre-
quency did not achieve the Hardy–Weinberg equilibrium in
the regular and/or early-onset patient group (Table 2),
indicating that, in particular, this SNP sites might be critical
for BCC formation. Finally, we observed that the overall
frequency of the 3944C/C genotype in our study was notably
lower than that in the study by Strange et al. However,
because we had not gathered control data from a normal
population of BCC-free individuals, we could not draw any
general conclusions about the significance of the 3944C/C
genotype in BCC.
Finally, the fact that we were unable to detect PTCH
mutations in over half of the BCC specimens we examined
(52% (31/60)) raises the possibility that other mechanisms
besides PTCH mutations may be involved in inactivating the
gene in many cases of sporadic BCC. For instance, somatic
mosaicisms (Soufir et al., 2006), promoter methylation,
haploinsufficiency, or other genes involved in the hedgehog
signalling pathway (Dahmane et al., 1997; Xie et al., 1998;
Reifenberger et al., 2005) may play a role. Consequently, we
have begun such studies.
MATERIALS AND METHODS
Patients and tumor samples
The BCC samples analyzed in this study were obtained from patients
who had been previously enrolled in an epidemiologic study of BCC
occurrence in the State of Styria, Austria (Ferra, 2002). That study
had been approved by the ethical committee of the Medical
University of Graz, Austria. All patients in that study had provided
tumor samples that were embedded in paraffin and subsequently
archived in the Histopathology Unit of the Department of
Dermatology at the Medical University of Graz. Those patients
who were still alive at the time of this study gave their informed
consent to DNA analysis of those tumor samples. The study was
conducted according to the Declaration of Helsinki Principles.
For this study, archived tumor samples were taken for DNA
analysis from three phenotypically distinct groups of 20 randomly
selected patients each. The three groups were defined as early-onset
BCC (i.e., a first BCC occurring before the age of 35 years) (group A) (3
men and 17 women; median age, 32.5 years; range 21–34 years;
median number of BCC, 1; range, 1–18), multiple BCC (i.e., X10
lesions) (group B) (11 men and 9 women; median age, 67 years; range
26–90 years; median number of BCC, 15; range, 10–36), and regular
BCC (i.e., a first BCC at the age of 35 years or older ando10 lesions)
(group C) (11 men and 9 women; median age, 69 years; range 45–77
years; median number of BCC, 1; range, 1–6). The body site location
of the BCC in the different patient groups was as follows: head and
neck, 10; trunk, 8; extremities, 0; and body site location not available,
2 for group A; head and neck, 11; trunk, 5; extremities, 4 for group B;
and head and neck, 13; trunk, 5; extremities, 2 for group C.
DNA extraction
DNA was extracted from the paraffin-embedded tumor samples as
follows. Formalin-fixed, paraffin-embedded tissue samples were
sliced into 5-mm-thick sections, placed on slides, deparaffinized with
xylene for 10 minutes, incubated in ethanol (100%) for 10 minutes,
and air dried. Samples were manually dissected to reduce the
proportion of non-tumor cells in the samples. Tissues were then
scraped off the slides and processed for DNA extraction using the
QIAquick gel extraction kit (Qiagen, Vienna, Austria).
PCR amplification of PTCH gene
The PTCH gene in tumor samples was amplified by PCR as follows.
The template for PCR consisted of 50–100 ng of tumor DNA in 50 ml
of a solution containing PCR-10 buffer (100 mM Tris-HCl, pH 8.3;
500 mM KCl), 1.5 mM MgCl2, 200 mM of each deoxyribonucleoside
triphosphate, 15 pmol (200 nM) of the upstream and downstream
primers for the respective exons 3–23, and 2.5 U of AmpliTaq Gold
Polymerase (Applied Biosystems, Vienna, Austria). PCR of exon 2
was performed in 50 ml of a solution containing PCR-10 buffer
(100 mM Tris-HCl, pH 8.3; 50 mM KCl, 15 mM MgCl2), 200mM of each
deoxyribonucleoside triphosphate, 15 pmol (200 nM) of the appro-
priate upstream and downstream primers, and 1.25 U of HotStar
polymerase (Applied Biosystems). The primer sequences of the
PTCH gene had been previously published (Hahn et al. 1996b; Xie
et al. 1997; Fujii et al., 2003). Reaction mixtures were subjected to
40 cycles of amplification in a thermocycler (MyCyclerTM; www.bio-
rad.com). Before the first cycle, tubes containing PCR mixtures were
incubated for 12 minutes at 941C (15 minute at 941C in the case of
PTCH exon 2). Each cycle consisted of denaturation at 941C for
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30 seconds, annealing at 55 or 601C for 30 seconds, and polymer-
ization at 721C for 1 minute. After the last cycle, PCR mixtures were
incubated at 721C for 10 minutes. PCR reaction tubes containing no
template DNA were included in each PCR run as negative controls
for potential contamination of PCR reactions. The amplified products
were then purified by gel electrophoresis on a 2.5% MetaPhor gel
(Cambrex; Rockland, ME, USA) and extracted from the gels using a
commercially available system, according to the manufacturer’s
recommended protocol (Wizards SV Gel and PCR clean-up system;
Promega; Mannheim, Germany).
Direct DNA sequencing
All purified DNA samples were sequenced using 3.2 pM of primer,
30 ng of DNA, and sequencing reagents (Big Dyes Terminator v1.1
Cycle Sequencing Kit; Applied Biosystems); purified on spin post-
reaction clean-up plates (Sigma-Aldrich, Vienna, Austria), and
separated in an ABI 3130 system (Applied Biosystems). Both DNA
strands were sequenced, and mutations on one strand were always
confirmed on the opposite strand. DNA samples from normal tissue
and placenta were analyzed simultaneously with the purified DNA
samples from tumor tissue in order to rule out PCR-generated
mutations. DNA sequence analysis was performed on a personal
computer equipped with SeqScapes software (Applied Biosystems).
Sequences were aligned according to GenBank entry U59464.
PTCH mutation classification
PTCH mutations were defined and classified as described previously
(Ichihashi et al., 2003 and references cited therein; Agar et al.,
2004). UV fingerprints were defined as C-T or tandem CC-TT
transitions at dipyrimidine sites. ROS fingerprints were defined as
G:C-T:A transversions. All other mutations (except deletions and
insertions) were defined as ‘‘other’’.
Statistical analysis
All statistical tests were two-sided at the 5% error level. In cases of
multiple testing, the family-wise error level was maintained by
Bonferroni correction (i.e., by dividing the significance level by the
number of tests performed). Fisher’s exact test was used for two-
group comparisons of relative mutation frequencies. A global test
(Goeman et al., 2004) was performed in order to test the difference
of SNP genotypes between groups. The homogeneity of allele
frequencies and the Hardy–Weinberg equilibrium were analyzed
using the exact w2-test and the R-packages ‘‘coin’’ and ‘‘genetics’’
(www.r-project.org). The uniformity of distribution of mutations on
the PTCH protein was tested using the exact tests for homogeneity of
Poisson distributions and the w2-test for independence of r by c tables
using StatXact 7 statistical software (www.cytel.com).
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